Central Pharma announces the acquisition of Biotechnica

Central Pharma announces the acquisition of Biotechnica

The leading pharmaceutical contract service provider Central Pharma has acquired Biotechnica, the UK’s largest manufacturer of seaweed extract.

The official acquisition was confirmed on Friday 5th February 2021.
Established in 1993, Biotechnica offers one of the most comprehensive ranges of agricultural biostimulants and biofertilisers and manufacture bespoke formulations.

Central Pharma specialises in the final stages of manufacturing and packaging for the pharmaceutical and nutraceutical industries and the acquisition brings benefit to both companies. With the market in seaweed extract growing globally, the company plan to expand vertically and where possible, invest sustainably.

“Our immediate focus is investment, to support growing demand from the existing Biotechnica customers. We are very excited to welcome Sam Brown, and her experienced team to the Central Pharma family”.

Alwyn Smit, CEO, Central Pharma

Working closely with their partners, the company plan to add value to this exciting area of wellness innovation. Central Pharma will expand production to meet the demand for this growing, nutraceutical market segment.

Biotechnica will be renamed as Central Pharma Biotechnica Limited and sit under the Central Pharma brand and logo.